BMS 770767

Drug Profile

BMS 770767

Alternative Names: BMS-770767

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antihyperglycaemics; Pyridines; Triazoles
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypercholesterolaemia; Type 2 diabetes mellitus

Most Recent Events

  • 31 May 2010 Phase-II clinical trials in Hypercholesterolaemia in Australia (PO)
  • 31 May 2010 Phase-II clinical trials in Hypercholesterolaemia in Canada (PO)
  • 31 May 2010 Phase-II clinical trials in Type-2 diabetes mellitus in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top